New cancer drug
News brief.
Research Headlines
New cancer drug
By Jeanne Sabatie, Production Editor
The FDA recently approved Gleevec for the treatment of chronic myelogenous leukemia. Gleevec was 16 years in the making and doesn't come cheapcosting up to $2,400 a month, although the manufacturer offers a sliding scale on the price in proportion to patients' income levels. Scientists report that the Novartis drug also seems to work for a cancer known as GIST (gastrointestinal stromal tumor). Though both cancers are rare, researchers hope to develop similar drugsthat kill cancer cells while sparing healthy onesfor many other cancers.
Jeanne Sabatie. New cancer drug.
Business and Health
2001;6:8.
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Healthcare journalist, HIV advocate and educator Juan Michael Porter II discussed moderating the "Future of Science" session at the International AIDS Society's AIDS 2024 meeting in Munich, Germany, as well as addressing "founder's syndrome" in AIDS organizations and the inclusivity of the event.
Read More
In our latest "Meet the Board" podcast episode, Managed Healthcare Executive Editors caught up with editorial advisory board member, Eric Hunter, CEO of CareOregon, to discuss a number of topics, one including the merger that never closed with SCAN Health Plan due to local opposition from Oregonians.
Listen
